Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Telaprevir’s Hidden Talents: New Data Show Effectiveness In Difficult To Cure Populations

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Groups with historically poor responses to standard hepatitis C therapy made good progress when the direct-acting antiviral telaprevir was added to their regimen, Vertex Pharmaceuticals Inc. reported at the American Association for the Study of Liver Diseases Meeting in Boston.

You may also be interested in...



Boceprevir Hep C Response-Guided Therapy Works For Experienced Patients

About half of experienced patients made enough progress to get into the shortened therapy group, and among them the cure rate was 86%.

Third Telaprevir Pivotal Study Raises Bar For Competitors Another Notch

Collective top-line data from the Phase III program testing Vertex Pharmaceuticals' protease inhibitor telaprevir in treatment-naïve and treatment-experienced hepatitis C patients set a high bar for competitors, particularly for Merck & Co.'s boceprevir, with which telaprevir is dueling to be the first approved specifically targeted antiviral therapy for hepatitis C (STAT-C).

Telaprevir ILLUMINATE Study May Light The Way To Shortened Hep C Treatment Time

Vertex released solid top-line data from a second Phase III study supporting a response-guided regimen that could halve the current 48-week standard course for many patients.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS004601

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel